Aurora, Illinois shooting

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Retrieved on: 
Tuesday, October 24, 2023
City, Bank, Health care, Agency for Healthcare Research and Quality, Hambrecht & Quist, City University, Vector Security, Bank of America, Immunotherapy, Autoimmune disease, Bernard, Derek Higgs, T1D, Aurora, Illinois shooting, Hambrecht, SAB, Alex. Brown & Sons, Pharmaceutical industry

SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), today announced that Michael G. King Jr. has been named Chief Financial Officer.

Key Points: 
  • SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), today announced that Michael G. King Jr. has been named Chief Financial Officer.
  • Mr. King received his BA in Finance from the Bernard M. Baruch College of the City University of New York.
  • “Mike has an outstanding track record of best-in-class relationships in the investment community and is a sought-after advisor for companies seeking strong value creation,” said Eddie J. Sullivan, Ph.D., co-founder, President, and Chief Executive Officer of SAB Biotherapeutics.
  • He’s been a wonderful colleague and the Board wishes him great success in his future endeavors.”
    Mr. King said, “It’s an exciting time to work for SAB.

SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update

Retrieved on: 
Monday, November 22, 2021
Research and development, Government, Cancer, SAB, Doctor of Philosophy, United States Department of Defense, COVID-19, Genetic engineering, TC, Aurora, Illinois shooting, Nasdaq, Twitter, Organ transplantation, R, Mutation, GLOBE, Knowledge, Infection, G&A, Immunotherapy, Licensure, Administration, Big Cypress National Preserve, Growth, Vaccine, Pharmaceutical industry

SIOUX FALLS, S.D., Nov. 22, 2021 (GLOBE NEWSWIRE) --  SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Nov. 22, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.
  • The business combination, which closed in October 2021, resulted in gross proceeds to SAB of approximately $30 million.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

Retrieved on: 
Tuesday, September 28, 2021
Oncology, Professional Services, Health, Other Health, Finance, Pharmaceutical, Biotechnology, Hewlett-Packard, Infection, Securities Act of 1933, Probability, DSMB, SAB, AstraZeneca, Therapy, Proxy, Sale, World Fuel Services, Organ transplantation, Private Securities Litigation Reform Act, Cancer, Multimedia, Registration statement, Teva Pharmaceuticals, TC, Teva, Business, Immunotherapy, Twitter, CEO, University, Communication, St. Lawrence University, Clorox, Register, COVID-19, Technology, Aurora, Illinois shooting, Big Cypress National Preserve, Genetic engineering, MBA, CFO, HBO, NIH, Forward-looking statement, Prospectus, Doctor of Philosophy, Government, Name, SEC, Pharmaceutical industry

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021.
  • Mr. Beyer brings more than 25 years of experience to SAB overseeing financial functions at pharmaceutical and other Fortune 100 firms including AstraZeneca, Teva Pharmaceuticals and HBO.
  • Mr. Beyer began his career at the Hewlett-Packard Company, where he ultimately served as a country chief financial officer.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.